Search

Your search keyword '"Bladé, Joan"' showing total 1,454 results

Search Constraints

Start Over You searched for: Author "Bladé, Joan" Remove constraint Author: "Bladé, Joan"
1,454 results on '"Bladé, Joan"'

Search Results

1. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

2. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

3. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

6. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

7. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease

9. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

10. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

11. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

12. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

13. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

15. Multiple Myeloma

16. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

18. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

19. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

20. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

22. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

23. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

27. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

28. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

30. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

32. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

33. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

34. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

35. Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution

36. OA-12 Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients

37. OA-20 Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial

38. P-045 Early treatment with bispecific T-cell redirectors (teclistamab or talquetamab) + daratumumab in newly diagnosed high-risk multiple myeloma: an open-label, phase 2, pilot study (GEM-TECTAL)

39. P-367 High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

42. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

43. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis

44. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation

45. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

47. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

49. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

50. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Catalog

Books, media, physical & digital resources